NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 275)
Posted On: 07/15/2021 3:31:38 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The company noted that these findings are strongly supportive of accelerated regulatory filings through the Food and Drug Administration (“FDA”) and other international regulators with the end goal of an accelerated market authorization process. The company anticipates pursuing collaboration opportunities with other pharmaceutical industry partners to incorporate its exclusive technology in other ways.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The company noted that these findings are strongly supportive of accelerated regulatory filings through the Food and Drug Administration (“FDA”) and other international regulators with the end goal of an accelerated market authorization process. The company anticipates pursuing collaboration opportunities with other pharmaceutical industry partners to incorporate its exclusive technology in other ways.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼